Migraine Treatment and Healthcare Resource Utilization in Alberta, Canada
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · 2024
DOI: 10.1017/cjn.2023.299 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2024. Verfasst von Erin Graves und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medlior Health Outcomes Research Ltd, Calgary, AB, Canada. Hauptthemen laut MEDLINE: Migraine Disorders, Patient Acceptance of Health Care. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Migraine poses a significant burden worldwide; however, there is limited evidence as to the burden in Canada. This study examined the treatment patterns, healthcare resource use (HRU), and costs among newly diagnosed or recurrent patients with migraine in Alberta, Canada, from the time of diagnosis or recurrence.
Methods
This retrospective observational study utilized administrative health data from Alberta, Canada. Patients were included in the Total Migraine Cohort if they had: (1) ≥1 International Classification of Diseases diagnostic code for migraine; or (2) ≥1 prescription dispense(s) for triptans from April 1, 2012, to March 31, 2018, with no previous diagnosis or dispensation code from April 1, 2010, to April 1, 2012.
Results
The mean age of the cohort (n = 199,931) was 40.0 years and 72.3% were women. The most common comorbidity was depression (19.7%). In each medication class examined, less than one-third of the cohort was prescribed triptans and fewer than one-fifth was prescribed a preventive. Among patients with ≥1 dispense, the mean rate of opioid prescriptions was 4.61 per patient-year, compared to 2.28 triptan prescriptions per patient-year. Migraine-related HRU accounted for 3%–10% of all use.
Conclusion
Comorbidities and high all-cause HRU were observed among newly diagnosed or recurrent patients with migraine. There is an underutilization of acute and preventive medications in the management of migraine. The high rate of opioid use reinforces the suboptimal management of migraine in Alberta. Migraine management may improve by educating healthcare professionals to optimize treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medlior Health Outcomes Research Ltd, Calgary, AB, Canada.
- Lundbeck Canada Inc, Montreal, QC, Canada.
- Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
ORCID-Profile: Erin Graves, Tram Pham
Zitieren
APA
Graves, E., Cowling, T., McMullen, S., Ekwaru, P., Pham, T., Mayer, M., Ladouceur, M. P., Hubert, M., Bougie, J., & Amoozegar, F. (2024). Migraine Treatment and Healthcare Resource Utilization in Alberta, Canada. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. https://doi.org/10.1017/cjn.2023.299
Vancouver
Graves E, Cowling T, McMullen S, Ekwaru P, Pham T, Mayer M, et al. Migraine Treatment and Healthcare Resource Utilization in Alberta, Canada. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 2024. doi:10.1017/cjn.2023.299
BibTeX
@article{Graves2024,
author = {Graves, Erin and Cowling, Tara and McMullen, Suzanne and Ekwaru, Paul and Pham, Tram and Mayer, Michelle and Ladouceur, Marie-Pier and Hubert, Martine and Bougie, Joanna and Amoozegar, Farnaz},
title = {Migraine Treatment and Healthcare Resource Utilization in Alberta, Canada},
journal = {Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques},
year = {2024},
doi = {10.1017/cjn.2023.299}
}
EUVIMED